|
|
|
|
Science Sparks @ ACTREC
|
 1st June 2026 |
Vol. No. 15 ; Issue No.737 |
|
|
Publications
|
|
1. Shafiq N, Kumar A, Cherian JJ, Madan T, Kshirsagar N, Mukherjee A, Vij S, Singh PK, Srivastava G, Visala A, Kumar A, Soman A, Kotakonda HK, Joglekar S, Joshi M, Udupa V, Poomali A, Noronha NB, Gogtay N, Krishnamurthy MN, Mohapatra S, Saha N, Gota V, Pradhan AK, Chatterjee P, Kumar A, Chaturvedi A, Balasundaram MK, Prakash G, Kakkar AK, Malhotra S (2026). Regulatory and ethical frameworks for first-in-human clinical trials in India: Proceedings of a codesigned capacity-building workshop. Clinical Drug Investigation.
2. Singh AG, Mahajan A, Sinha S, Shetty R, Mohanty S, Kumar A, Chakrabarty N, Joshi P, Nair S, Laskar SG, Prabhash K, Chaturvedi P (2026). Tumour growth kinetics and stage progression during treatment delay in oral squamous cell carcinoma. Oral Oncology
3. Juneja A, Sahay A, Padwale P, Patil A, Pai T, Panjwani P, Joshi S, Wadasadawala T, Popat P, Shet TM, Gupta S, Desai SB (2026). Concordance of conventional two-tier HER2 classification versus three-tier classification (including HER2-low status) in invasive breast carcinoma: a retrospective real-world analysis. Journal of Clinical Pathology
4. Shinde P, Ak A, Agarwal P, Kamalnath J, Joshi K, Prajapati K, Jain J, Mulani J, Gupta A, Mittal P, Sawant P, Agarwal JP, Cozzi L, Chopra S (2026). Spatially fractionated radiotherapy using straight and bending virtual rods as an alternative for cervical cancer brachytherapy-results from preclinical in-silico dose comparison and quality assurance. British Journal of Radiology
5. Sakhare N, Muralidharan S, Kumar D, Dutta S, Gnanasekar R, Paradkar S, Mitra A, Mohanty B, Mirapurkar A, Mathur A, Chaudhari P, Bose K (2026). Synthesis and evaluation of 99mTc essential analogue of DUPA PSMA inhibitor for its potential use in prostate cancer imaging. ChemistrySelect. 11(21): e06967.
6. Noguera NI, Hasan SK and Cicconi L (2026) Evaluating differentiation therapy and biomarkers in myeloid malignancies. Frontiers in Oncology. 16:1867602.
7. Dey S, Anne S, Rath S, Nandhana R, Gulia S, Dash B, Menon S, Rekhi B, Baheti A, Sable N, Popat P, Tandon S, Ghosh K, Gurram L, Parab SS, Logkumer AN, Jhadhav S, Chopra S, Surappa ST, Bansal V, Balsarkar G, Deodhar K, Maheshwari A, Ghosh J, Gupta S (2026). Malignant ovarian germ cell tumor-survival and reproductive outcomes and patterns of relapse. Cancer Medicine. 15(6):e71936.
|
|
|
|
|
Interesting Reads
|
|
Schenker M, Tebbutt NC, Ajani J, Salimin N, Ku G, Gwang Kim J, Ales Diaz I, Zhang J, Pietrantonio F, Bai LY, Le Sourd S, Zhao J, Hierro C, Kiberu A, Van Herpe F, Bao Y, Zhang H, Yang L, Li V, Gartner EM, Chen Y, Grim J, Rha SY, Shen L (2026); HERIZON-GEA-01 Investigators. Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer. New England Journal of Medicine.
|
|
|
Video of the Week
|
|
| The New Era of mHSPC Treatment: Evaluating Emerging Doublet and Triplet Combinations |
|
| |
|
|
| |
|
|
|
|
Do You Know?
In 1915, Katsusaburo Yamagiwa and Koichi Ichikawa induced cancer in rabbits by applying coal tar to their skin, providing experimental proof that chemicals can cause cancer.
|
|
|
|
Cancer News
|
| |
|
New AI model predicts cancer treatment responses from mutations.
|
|
News-Medical.Net, 26/05/2026
|
|
The researchers emphasize that the model was designed not only to make predictions, but also to provide insight into why those predictions are made, which could help when refining biomarkers and treatment strategies...
|
| |
|
FDA Approves Pivekimab Sunirine for Rare Blood Cancer.
|
|
Oncology News Central, 28/05/2026
|
|
Sthe U.S. Food and Drug Administration (FDA) approved pivekimab sunirine-pvzy (Decnupaz) for adults with the rare hematologic malignancy blastic plasmacytoid dendritic cell neoplasm (BPDCN). BPDCN is a rare and aggressive hematologic malignancy with historically limited treatment options...
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
2026 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|
